The company's share capital will thus rise to 805m shares.
Pharming also said it had presented to the shareholders alternatives to deal with its negative equity situation. The company pointed it expects a milestone payment of up to USD15m (EUR11.5m) from successful finalisation of a US study.
Pharming announced last December a negative equity capital referring to among others changes needed to comply with the IFRS accounting requirements.
(USD1 = EUR0.764)
Aptamer Optimer technology integrated into Twist Bioscience TrueAmp Library Preparation Kit
Alvotech reports positive PK study results for AVT80 biosimilar candidate
Inspiration Healthcare secures US purchasing agreement to drive Airon growth
West to sell SmartDose 3.5mL On-Body Delivery System rights to AbbVie for USD112.5m
Sanofi receives FDA complete response letter for tolebrutinib in progressive MS
Abbott announces quarterly common dividend increase
Amgen announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Perrigo to pay quarterly dividend of USD0.290 per share
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma